Lymphocytic Leukemia, Chronic — CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
Citation(s)
An Open Label Phase Ia/b Dose Escalation Followed by Dose Expansion Safety and Tolerability Trial of CAP-100, a Humanized C-C-chemokine Receptor 7 Antibody, Administered as Monotherapy in Subjects With r/r Chronic Lymphocytic Leukemia